%0 Journal Article %1 bencherif2015injectable %A Bencherif, Sidi A %A Sands, R Warren %A Ali, Omar A %A Li, Weiwei A %A Lewin, Sarah A %A Braschler, Thomas M %A Shih, Ting-YS %A Verbeke, Catia S %A Bhatta, Deen %A Dranoff, Glenn %A Mooney, David J %D 2015 %J Nature Communications %K cancer immuneSystem methods vaccine %N 7556 %R 10.1038/ncomms8556 %T Injectable Cryogel-based Whole Cell Cancer Vaccines %U https://www.nature.com/articles/ncomms8556 %V 6 %X A biomaterial-based vaccination system that uses minimal extracorporeal manipulation could provide in situ enhancement of dendritic cell (DC) numbers, a physical space where DCs interface with transplanted tumour cells, and an immunogenic context. Here we encapsulate GM-CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels. These cryogels are injected subcutaneously into mice to localize transplanted tumour cells and deliver immunomodulatory factors in a controlled spatio-temporal manner. These vaccines elicit local infiltrates composed of conventional and plasmacytoid DCs, with the subsequent induction of potent, durable and specific anti-tumour T-cell responses in a melanoma model. These cryogels can be delivered in a minimally invasive manner, bypass the need for genetic modification of transplanted cancer cells and provide sustained release of immunomodulators. Altogether, these findings indicate the potential for cryogels to serve as a platform for cancer cell vaccinations.

@article{bencherif2015injectable, abstract = {A biomaterial-based vaccination system that uses minimal extracorporeal manipulation could provide in situ enhancement of dendritic cell (DC) numbers, a physical space where DCs interface with transplanted tumour cells, and an immunogenic context. Here we encapsulate GM-CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels. These cryogels are injected subcutaneously into mice to localize transplanted tumour cells and deliver immunomodulatory factors in a controlled spatio-temporal manner. These vaccines elicit local infiltrates composed of conventional and plasmacytoid DCs, with the subsequent induction of potent, durable and specific anti-tumour T-cell responses in a melanoma model. These cryogels can be delivered in a minimally invasive manner, bypass the need for genetic modification of transplanted cancer cells and provide sustained release of immunomodulators. Altogether, these findings indicate the potential for cryogels to serve as a platform for cancer cell vaccinations.}, added-at = {2017-12-02T23:43:34.000+0100}, author = {Bencherif, Sidi A and Sands, R Warren and Ali, Omar A and Li, Weiwei A and Lewin, Sarah A and Braschler, Thomas M and Shih, Ting-YS and Verbeke, Catia S and Bhatta, Deen and Dranoff, Glenn and Mooney, David J}, biburl = {https://www.bibsonomy.org/bibtex/2ce9047a230e29eea25d810b197675098/artheibault}, description = {This article describes a new method for creating whole-cell vaccines to treat cancer. Irradiated cells obtained from mouse models are infused into cryogels before being injected. The vaccines appeared to have a positive impact on tumor suppression. The researchers hope that this technology will allow for the production of personalized vaccines requiring minimal manipulation of the cells themselves.}, doi = {10.1038/ncomms8556}, interhash = {924226fdf36fa804fc96d6bf6cea1af9}, intrahash = {ce9047a230e29eea25d810b197675098}, journal = {Nature Communications}, keywords = {cancer immuneSystem methods vaccine}, month = aug, number = 7556, timestamp = {2017-12-02T23:43:34.000+0100}, title = {Injectable Cryogel-based Whole Cell Cancer Vaccines}, url = {https://www.nature.com/articles/ncomms8556}, volume = 6, year = 2015 }